How to advance your combination therapy development programs using this new bioinformatics solution
How to evaluate and quantify two-drug combination effects (synergistic, antagonistic, and additive) for in vitro cell-based assays
To easily visualize and understand dose-response curve graphs, combination index graphs, inhibition heat maps for concentration combinations, 2-D contour maps, and 3D response surface plots
The key differentiators between in vitro systems, including conventional 2D platforms, 3D cultures including patient-derived models, and tumor organoids
How to select the right 3D in vitro platform for each stage of your drug development program based on model features, benefits, and limitations
How tumor organoids provide a superior and predictive research system for oncology drug development applications
The main applications of tumor organoids including high throughput screening, immunotherapy assessment, and enhanced in vivo model selection
About this robust and reproducible ex vivo 3D assay platform that uses cells isolated from early passage PDX models
That there is over 70% correlation is shown in a retrospective analysis of in vivo data with our ex vivo results
How these panels can be used for standard of care drug screening, with varying efficacy observed for SoC agents tested across the colorectal PDX cell model panel
The importance of cell line selection, using collated databases containing large cell line collections, or bespoke model creation
How to select the correct downstream molecular biology assays to assess target expression, drug target inhibition, and tumor growth inhibition
How an integrated in vitro, ex vivo, and in vivo oncology portfolio allows go/no go decisions to be made with confidence, using a single, uniquely positioned provider